Omics Approaches in Drug Development against Leishmaniasis: Current Scenario and Future Prospects
-
Published:2022-12-26
Issue:1
Volume:12
Page:39
-
ISSN:2076-0817
-
Container-title:Pathogens
-
language:en
-
Short-container-title:Pathogens
Author:
Rabaan Ali A.ORCID, Bakhrebah Muhammed A.ORCID, Mohapatra Ranjan K.ORCID, Farahat Ramadan AbdelmoezORCID, Dhawan ManishORCID, Alwarthan Sara, Aljeldah MohammedORCID, Al Shammari Basim R.ORCID, Al-Najjar Amal H.ORCID, Alhusayyen Mona A., Al-Absi Ghadeer H.ORCID, Aldawood Yahya, Alsaleh Abdulmonem A.ORCID, Alshamrani Saleh A., Almuthree Souad A., Alawfi Abdulsalam, Alshengeti AmerORCID, Alwashmi Ameen S. S.ORCID, Hajissa KhalidORCID, Nassar Majed S.ORCID
Abstract
Leishmaniasis is a zoonotic disease transmitted in humans by the bite of Leishmania-infected phlebotomine sandflies. Each year approximately 58,500 cases of leishmaniasis are diagnosed across the globe, with a mortality rate of nearly seven percent. There are over 20 parasitic strains of Leishmania which are known to cause distinct types of leishmaniasis and pose an endemic threat to humans worldwide. Therefore, it is crucial to develop potential medications and vaccines to combat leishmaniasis. However, the task of developing therapeutic solutions is challenging due to Leishmania’s digenetic lifecycle. The challenge is further intensified by cases of resistance against the available drugs. Owing to these challenges, the conventional drug development regimen is further limited by target discovery and ligand suitability for the targets. On the other hand, as an added advantage, the emergence of omics-based tools, such as high-end proteomics, transcriptomics and genomics, has hastened the pace of target discovery and target-based drug development. It is now becoming apparent that multi-omics convergence and an inter-connected systems approach is less time-consuming and more cost-effective for any drug-development process. This comprehensive review is an attempt to summarize the current knowledge on the muti-omics approach in drug development against leishmaniasis. In particular, it elaborates the potential target identification from secreted proteins in various stages of Leishmania infection and also illustrates the convergence of transcriptomic and genomic data towards the collective goal of drug discovery. This review also provides an understanding of the potential parasite’s drug targets and drug resistance characteristics of the parasite, which can be used in designing effective and specific therapeutics.
Subject
Infectious Diseases,Microbiology (medical),General Immunology and Microbiology,Molecular Biology,Immunology and Allergy
Reference98 articles.
1. Leishmaniasis: A Review;Arenas;F1000Research,2017 2. Leishmaniasis;Piscopo;Postgrad. Med. J.,2007 3. Drug discovery in leishmaniasis using protein lipidation as a target;Brannigan;Biophys. Rev.,2021 4. Alvar, J., Vélez, I.D., Bern, C., Herrero, M., Desjeux, P., Cano, J., Jannin, J., and den Boer, M. (2012). The WHO Leishmaniasis Control Team Leishmaniasis Worldwide and Global Estimates of Its Incidence. PLoS ONE, 7. 5. Prevention, C.-C. (2022, July 25). For D.C. and CDC-Leishmaniasis-Epidemiology & Risk Factors, Available online: https://www.cdc.gov/parasites/leishmaniasis/epi.html.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Leishmaniasis;Rising Contagious Diseases;2024-01-05 2. Drug discovery in Africa tackles zoonotic and related infections;Science Translational Medicine;2023-10-18
|
|